March 22, 2022 7:34am

Volatility puts sector on notice regulating directional motion

Financing: Applied Genetic Technologies (AGTC) closed down -$0.08 to $1.80 with a negative -$0.40 or -22.22% pre-open indication after news of a proposed offering and debt “deal” managed by Cantor Fitzgerald & Co – BAD timing and DESPARATE move!

Pre-open indications: 2 SELLs, 2 BUYs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.46% (+159 points), S&P futures are UP +0.29% (+13 points) and NASDAQ futures are UP +0.19% (+27 points)

 

Stock index futures rose tip-toed forward Tuesday, yet look questionable to rebound from a down session,

European stocks inched higher as the pan-European Stoxx 600 gained 0.5% by late morning, with health care stocks falling -0.7%,

Asia-Pacific stocks were mixed, as China Eastern Airlines shares fell after the carrier’s Boeing 737 passenger jet crashed in southern China on Monday.

 

Henry’omics:

The Dow fell 201.94 points, or 0.6%, breaking a five-day winning streak, the S&P 500 finished after rising +0.4% during the session, while the Nasdaq fell -0.4% to 13,838.46 after dipping as much as -1.5% at session lows.

“Wall Street was coming off a volatile session Monday, as Powell vowed to take “necessary steps” to curb inflation less than a week after the agency raised rates for the first time since 2018. Powell said “inflation is much too high” and added that rates could increase more than the previously approved 25 basis points if needed.” <CNBC>

 

RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: The sector got whacked as the electronics and algorithms ate through any upside.” … https://www.regmedinvestors.com/articles/12351

Ebb and flow –

·         March – 8 negative and 7 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  (CRBU) added, 29 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL:

Applied Genetic Technologies (AGTC) closed down -$0.08 to $1.80 with a negative -$0.40 or -22.22% pre-open indication after news of a proposed offering and debt “deal” managed by Cantor Fitzgerald & Co – BAD timing and DESPARATE move!

Ionis Pharmaceuticals (IONS) closed down -$0.33 to $34.92 after Friday’s +$0.49, Thursday’s +$0.78 and Wednesday’s +$1.28 with a negative -$0.56 or -1.60% pre-open indication.

 

BUY:

Chinook Therapeutics (KDNY) closed -$0.26 to $14.74 with a positive +$0.35 or +2.37% pre-open indication.

Sangamo Therapeutics (SGMO) closed down -$0.39 to $5.78 with a positive +$0.37 or +6.40% pre-open indication.

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed flat again on Monday with 5 shares traded after Friday’s flat with 26 shares traded after Thursday’s up +$0.47 with 1,737 shares traded after Wednesday’s flat with 765 shares traded and last Tuesday’s -$0.30 to $4.00 with 380 shares traded, …

WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …

BSTG is NOT going ANYWHERE without a cash infusion.

 

The BOTTOM LINE: In MY mind, buying opportunities are scant after a dramatic dive session, enabling more of a downtrend.

As I stated Monday a.m., after a four (4) session sector rally are you as an investor willing to wait-it-out for the falling knife?

It fell and could keep falling further!

This market remains at the mercy of the latest headline as war and killing news, fed questions and the lack of positive sector news is the bane of March lifting or sinking the major indexes.

Caution is still in order. The sector should begin to struggle, with some equities slipping from highs. I say, cut or partially sell into strength without totally removing some names.

There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another eight (8) are due.

There is no clear trend ….

Earnings’ reporting on the horizon:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

 

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!